Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Smell

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    103 result(s) found for: Smell. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2010-024438-52 Sponsor Protocol Number: 1-2011 Start Date*: 2011-09-05
    Sponsor Name:Fakultní nemocnice v Motole
    Full Title: Impaired sense of smell and its conservative tratment in patients with chronic rhinosinusitis
    Medical condition: The proposed clinical study on impaired sense of smell in patients with chronic rhinosinusitis.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-004021-71 Sponsor Protocol Number: NL.78693.041.21 Start Date*: 2021-10-13
    Sponsor Name:University Medical Center Utrecht
    Full Title: COrticosteroids for COVID-19 induced loss of Smell – COCOS trial
    Medical condition: Loss of smell after COVID-19 infection, persisting after 4 weeks
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-003896-37 Sponsor Protocol Number: BronSin2013 Start Date*: 2014-01-28
    Sponsor Name:URSAPHARM Arzneimittel GmbH
    Full Title: Efficacy and tolerability of Bromelain tablets hysan® in patients with chronic rhinosinusitis. A prospective, double-blind, randomized, placebo-controlled multi-centre trial. A proof of concept stu...
    Medical condition: Patients suffering from chronic rhinosinusitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000829-27 Sponsor Protocol Number: LPS16747 Start Date*: 2021-09-23
    Sponsor Name:Sanofi-aventis Recherche & Développement
    Full Title: A randomized, double-blind, head-to-head comparison of dupilumab versus omalizumab in severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and comorbid asthma patients
    Medical condition: Chronic rhinosinusitis with nasal polyps
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038738 - Respiratory, thoracic and mediastinal disorders 10080060 Chronic rhinosinusitis with nasal polyps PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) BE (Completed) CZ (Completed) FI (Completed) HU (Completed) SE (Completed) ES (Ongoing) DK (Completed) PT (Completed) PL (Completed) IT (Completed) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002073-22 Sponsor Protocol Number: CQAW039A2322 Start Date*: 2018-12-13
    Sponsor Name:Novartis Pharma AG
    Full Title: A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of fevipiprant once daily plus standard-of-care (SoC) for assessment of the efficacy in reduction of nasal polyps s...
    Medical condition: Nasal polyposis in patients with concomitant asthma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10028756 Nasal polyps PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) CZ (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003062-39 Sponsor Protocol Number: D5242C00001 Start Date*: 2021-03-18
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Participants with Severe Chronic Rhinosinusitis with Nasal Polyposis...
    Medical condition: Severe Chronic Rhinosinusitis with Nasal Polyposis
    Disease: Version SOC Term Classification Code Term Level
    27.0 10038738 - Respiratory, thoracic and mediastinal disorders 10080060 Chronic rhinosinusitis with nasal polyps PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) HU (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001682-33 Sponsor Protocol Number: GB001-2101 Start Date*: 2019-09-09
    Sponsor Name:GB001, Inc.
    Full Title: A Phase 2a, randomized, double-blind, placebo-controlled, multi-center study to evaluate the effect of GB001 in patients with chronic rhinosinusitis with or without nasal polyps
    Medical condition: Chronic Rhinosinusitis with or without Nasal Polyps
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10071399 Chronic eosinophilic rhinosinusitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2020-000421-76 Sponsor Protocol Number: AirGOs-biologics Start Date*: 2020-04-15
    Sponsor Name:Helsinki University Hospital
    Full Title: Aggravated airway inflammation: research on biological treatment (Mepolizumab) AirGOs-biologics
    Medical condition: A triad of chronic rhinosinusitis with nasal polyps (CRSwNP), asthma and NSAID exacerbated respiratory disease (NERD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000851-42 Sponsor Protocol Number: ID-084A201 Start Date*: 2018-07-27
    Sponsor Name:Idorsia Pharmaceuticals Ltd
    Full Title: A randomized, double-blind, placebo-controlled, 12-week treatment study to evaluate the effect of ACT-774312 in subjects with bilateral nasal polyposis
    Medical condition: Bilateral nasal polyposis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10028756 Nasal polyps PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000195-38 Sponsor Protocol Number: D3252C00004 Start Date*: 2020-11-18
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab for the Prevention of Recurrence of Nasal Polyps Following Surgical Rem...
    Medical condition: Nasal polyposis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10028754 Nasal polyp LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003101-42 Sponsor Protocol Number: EFC14146 Start Date*: 2016-11-18
    Sponsor Name:SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT
    Full Title: A Randomized, 24-Week Treatment, Double-blind, Placebo-controlled Efficacy and Safety Study of Dupilumab Every Other Week, in Patients with Bilateral Nasal Polyposis on a Background Therapy with In...
    Medical condition: nasal polyps
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10028756 Nasal polyps PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) DE (Completed) NL (Completed) CZ (Completed) FR (Completed) PL (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-001314-10 Sponsor Protocol Number: EFC14280 Start Date*: 2016-11-29
    Sponsor Name:SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT
    Full Title: A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients with Bilateral Nasal Polyposis on a Background Therapy with Intranasal Corticosteroids
    Medical condition: Bilateral nasal polyposis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10028756 Nasal polyps PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) PT (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-005055-36 Sponsor Protocol Number: 218079 Start Date*: 2022-04-15
    Sponsor Name:GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
    Full Title: A randomised, double-blind, parallel group Phase III study to assess the efficacy and safety of 100 mg SC depemokimab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) – ANCHOR-2 (...
    Medical condition: Chronic Rhinosinusitis with Nasal Polyps
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038738 - Respiratory, thoracic and mediastinal disorders 10080060 Chronic rhinosinusitis with nasal polyps PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SE (Completed) ES (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005037-16 Sponsor Protocol Number: 217095 Start Date*: 2022-05-17
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A randomised, double-blind, parallel group Phase III study to assess the efficacy and safety of 100 mg SC depemokimab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) – ANCHOR-1 (...
    Medical condition: Chronic Rhinosinusitis with Nasal Polyps
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038738 - Respiratory, thoracic and mediastinal disorders 10080060 Chronic rhinosinusitis with nasal polyps PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) DE (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001724-22 Sponsor Protocol Number: GA39688 Start Date*: 2017-12-21
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
    Medical condition: Chronic rhinosinusitis with nasal polyps
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10028756 Nasal polyps PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) CZ (Completed) PT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-001718-28 Sponsor Protocol Number: GA39855 Start Date*: 2018-02-19
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
    Medical condition: Chronic rhinosinusitis with nasal polyps
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10028756 Nasal polyps PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) ES (Completed) FI (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-005074-24 Sponsor Protocol Number: Feb-02 Start Date*: 2005-02-23
    Sponsor Name:Febena Pharma GmbH
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF AN OINTMENT FORMULATION CONTAINING DEXAMETHASONE IN PATIENTS WITH RHINOSINUSITIS A CLINICAL PHASE IV ...
    Medical condition: Patients with allergy-induced, non-infectious diseases of the nasal mucosa (e. g. hay fever) and the sinuses.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10052106 Rhinosinusitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002368-42 Sponsor Protocol Number: LUM-001 Start Date*: 2017-10-12
    Sponsor Name:Lument AB
    Full Title: An open, randomized, controlled, single centre trial to evaluate CT image quality and diagnostic feasibility of Lumentin® 44, a new egg albumen based oral bowel filling agent, in comparison with di...
    Medical condition: None. Lumentin 44 is a contrast agent and the contrast properties will be investigated in this trial. Patients referred to computerised tomography of the abdomen will be included in the trial. Nei...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004848 10011603 CT scan LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002414-12 Sponsor Protocol Number: 12082.101 Start Date*: Information not available in EudraCT
    Sponsor Name:PARI Pharma GmbH
    Full Title: A randomised, open, controlled pilot study to investigate the efficacy and safety of Buparid/PARI SINUS versus Budes® Nasal Spray in the therapy of Chronic Rhinosinusitis (CRS) with polyposis nasi ...
    Medical condition: Chronic Rhinosinusitis (CRS) with polyposis nasi
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002421-30 Sponsor Protocol Number: 12082.102 Start Date*: 2014-06-06
    Sponsor Name:PARI Pharma GmbH
    Full Title: A randomised, open, controlled pilot study to investigate the potential of Buparid/PARI SINUS versus Budes® Nasal Spray to avoid or postpone sinus surgery in adult patients with Chronic Rhinosinu...
    Medical condition: Chronic Rhinosinusitis (CRS)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 02:34:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA